India’s most profitable large company is a familiar, if unexpected, one

With a net margin of 41%, that distinction goes to Serum Institute of India, the country’s leading maker of covid-19 vaccines. It is in good shape to earn profits from the sale of covid-19 vaccines. But with its robust financial position, has it done enough on the investing and pricing side to earn the respect and goodwill of a pandemic-stricken nation?

You are here: Home